

418 Rec'd PCT/PTO 1 4 MAY 1999

TRANSMITTAL LETTER FOR A PCT INTERNATIONAL APPLICATION
ENTERING THE NATIONAL STAGE IN THE U.S.
AS A DESIGNATED or ELECTED OFFICE UNDER 35 USC 371

Attorney's Docket No.: HASLP003

Date: May 14, 1999

Express Mail" mailing label number (from mail label): **EL243914071**

Date of Deposit: May 14, 1999

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service, as required under 37 CFR 1.10, on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT Application, Washington, D.C. 20231.

Name:

Dionna Holmes

Signature:

Dionna Holmes

Assistant Commissioner for Patents
Box PCT Application
Washington, D.C. 20231

15 SEP 1999

Attention: DO/EO/US

Transmitted herewith are the papers required to enter the national state in the U.S. as a designated office/elected office for the following PCT international patent application:

INTERNATIONAL APPLICATION NUMBER: PCT/GB97/03152

Int'l Filing Date: 17 November 1997

1st Priority Date: 16 November 1996

Inventor(s): MAYES, Eric, Leigh
TYLER, Malvin, Nicolas

For: **MAGNETIZABLE DEVICE**

The United States Patent Office is: (select one)

A Designated Office (No Demand was filed - See 37 CFR 1.494)

X An Elected Office (A Demand for Preliminary Examination was Filed - See 37 CFR 1.495)

Enclosed are:

X This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).

— A copy of the international application (if this line is not checked, the international application was previously communicated by the International Bureau or the international application was originally filed in the USPTO).

An English Translation of the International Application

A Combined Declaration and Power of Attorney

A copy of amendments made under PCT Article 19

A translation of amendments made under PCT Article 19

A translation of annexes to the international preliminary examination report.

Verified Statement establishing Small Entity Status under 37 CFR 1.9 and 1.27.

An Assignment of the Invention to: ***.

(with \$40.00 recordal fee)

Information Disclosure Statement

- ☐ A Preliminary Amendment
☒ A copy of the International Search Report
☒ A copy of the Preliminary Examination Report
☒ A check to cover the filing fees (including the basic national fee under 37 CFR 1.492(a)) in the amount calculated below:

FEE CALCULATION

<input checked="" type="checkbox"/>	BASIC FEE					\$930
	(IPEA-U.S. \$720/360; ISA-U.S. \$790/395; PTO not ISA or IPEA \$1070/535;					
	U.S. IPEA all claims meet 33(2)-(4) \$98/49; File w/ EPO or JPO search report \$930/465;)					
	Surcharge for filing a late oath or declaration (\$130/65)				\$ ***	
	Surcharge for filing a late translation (\$130)				\$ ***	
<input checked="" type="checkbox"/>	Multiple dependent claims (\$270/135)					\$ 270
	Excess claims - see calculation below					\$ ***
	Total Claims:	16	-	20	=	0
	Independent Claims:	2	-	3	=	0
				X	\$22/11 claim =	\$ -0-
				X	\$82/41 ind. claim =	\$ -0-
					Excess Claim Total	\$ -0-
	Assignment recordal fee (\$40)					\$ ***
					TOTAL FEES	\$1200

Please direct any correspondence to:

Customer Number: 022434
BEYER & WEAVER, LLP
P.O. Box 61059
Palo Alto, CA 94306



22434

PATENT TRADEMARK OFFICE

☒ The Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account No. 50-0388. A duplicate copy of this transmittal is enclosed.

Respectfully submitted.

Joseph M. Villeneuve
Registration No. 37,460

BEYER & WEAVER, LLP
P.O. BOX 61059
Palo Alto, CA 94306
(650) 493-2100

Applicant/Patentee: MAYES and TYLER

Application or Patent No. 09/308,166 Atty Docket # HASLP003

Filed or Issued: 17 November 1997

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
37 CFR 1.9(f) and 1.27(c)--SMALL BUSINESS CONCERN

I hereby declare that I am

☐ the owner of the small business concern identified below:

☒ an official empowered to act on behalf of the small business concern identified below:

NAME OF CONCERN: NANOMAGNETICS LIMITED

ADDRESS: 9 The Circus, Bath BA1 2EW, Great Britain

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under 41(a) and (b) of Title 35, U.S. Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled: MAGNETIZABLE DEVICE

, by inventor(s) Eric Leigh MAYES and
Malvin Nicolas TYLER, described in

☐ the specification filed herewith.

☒ Application No. PCT/GB97/03152 filed 17th November 1997

☐ patent # _____ issued _____

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*Note: separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

Name: _____

Address: _____

☐ individual ☐ small business concern ☐ nonprofit organization



I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 1001 of Title 18 of the U.S. Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: Mr. MALVIN NICOLAS TYLER

TITLE IN ORGANIZATION: DIRECTOR

SIGNATURE [Signature] DATE MAY 17 1998



A NITROIMIDAZOLE GEL COMPOSITIONDESCRIPTION

5

The present invention relates to viscous, jelly or cream like, pharmaceutical compositions for skin application, preferably for use in topical treatments of skin which is intolerant of exposure to aqueous preparations of non-physiological pH, or of excessive hypo- or hypertonicity. The invention also relates to a method of preparing such compositions.

10

Antimicrobially active imidazole derivatives, such as the nitroimidazole compounds metronidazole and tinidazole, can be used in the topical treatment of certain dermatological diseases, including rosacea and eczema, in which the skin becomes dry or inflamed, or is predisposed to becoming dry or inflamed when exposed to aqueous media. Dry or inflamed skin is highly intolerant of exposure to water based formulations with a pH outside the physiologically acceptable range of approximately pH 5-6, or which exert a physiologically incompatible osmotic pressure. Thus, topically applied aqueous compositions with an inappropriately high or low pH, or which exert an incompatible osmotic pressure, not only have the potential to cause irritation and stinging, but their use can actually worsen the symptoms of a disease.

15

20

With some active agents, this problem can be overcome by employing oil based formulations. However, many antimicrobially active imidazole derivatives are

25

substantially insoluble in such non-polar vehicles and, therefore, cannot be formulated in this manner.

One known aqueous based metronidazole gel composition includes lactic acid both as an humectant and in order to increase the solubility of the metronidazole.

However, the presence of lactic acid in this formulation causes it to have a low pH and to be prone to causing an unacceptable degree of irritation to dry, sensitive or disease inflamed skin.

Other known topical metronidazole formulations include cross-linked polymers of acrylic acid, sold under the registered trade mark CARBOPOL, as thickening agents. Although it is possible to use such thickeners to prepare gels with a pH in the range of 5-6, unless great care is exercised during the manufacture of formulations employing these materials, they can form clumps which are insoluble, due to the formation of a water impregnable layer around the clump interior, and which cannot be reduced or dissolved once formed. In such circumstances, hydration of the resin will be incomplete and the result can be broad pH fluctuations in the final product. Moreover, polyacrylic acid resins are sensitive to salts and cations and are not stable in the presence of more than about 0.1% of strongly ionizable salts, particularly those with multivalent cations, such as calcium, magnesium, iron and aluminium salts. Thus, not only is it difficult to manufacture such formulations consistently within an acceptable (narrow) pH range, but it may

also be impossible to include therein a sufficient amount of ionic material to achieve an ideal pH, mitigate clumping induced pH variation, or to achieve a skin compatible osmotic pressure.

- 5 An object of the present invention is to provide a viscous composition useful in the topical treatment of highly sensitive skin with water soluble active agents, such as metronidazole, which is less prone to irritate inflamed or sensitive skin and which is more easily and more readily manufactured than known such products.
- 10 In a first aspect, the present invention provides a method for preparing a viscous hydrogel composition, for use in a topical treatment of a skin condition involving dry or inflamed skin, including a pharmaceutically active agent, a polysaccharide, a water-miscible organic solvent and water, comprising the steps of suspending the polysaccharide in the water-miscible organic solvent and mixing the resulting
- 15 polysaccharide suspension into the aqueous medium, thereby to hydrate the polysaccharide and to form a viscous hydrogel composition, wherein the pharmaceutically active agent is an antimicrobially active nitroimidazole drug, the water-miscible organic solvent is a water-miscible alkylene glycol, and the composition is buffered to have a pH within the range of 4.5-6.5. The
- 20 polysaccharide, preferably acts as a gelling or thickening agent. An advantage of this aspect of the invention is that it enables clumping of the polysaccharide, and consequential broad pH fluctuations in the final product, to be avoided and thereby allows the aforementioned object of the invention to be achieved.
- 25 Preferably, the aqueous medium comprises a previously formed aqueous solution of the nitroimidazole drug. Alternatively or additionally, the active agent

can be mixed with the water-miscible organic solvent before the suspension is mixed with the aqueous medium. In this alternative procedure, the active agent can be suspended or dissolved in the water-miscible organic solvent and is preferably mixed therewith before the polysaccharide is suspended therein.

5

The active agent can be dissolved in water at a temperature of 15-50°C, 25-40°C and, preferably, 35-40°C (to provide the aqueous medium) and the suspension of polysaccharide can be at a temperature of 4-30°C, preferably 15-25°C, or 4-15°C, preferably 10-15°C, immediately prior to mixing with the aqueous medium. It is preferred for the polysaccharide to be insoluble or substantially insoluble in the organic solvent.

10

In an embodiment of the first aspect of the invention, the polysaccharide is preferably a non-ionic cellulose ester, ether, hydroxy-ether, or hydroxy-ester, or a non-ionic starch derivative. The polysaccharide can be a methyl, ethyl or propyl cellulose ester, ether, hydroxy-ether or hydroxy-ester. Preferably, the polysaccharide is a hydroxyalkyl cellulose.

15

In accordance with a second aspect of the present invention there is provided a viscous hydrogel composition, for use in a topical treatment of a skin condition involving dry or inflamed skin, comprising an antimicrobially active nitroimidazole drug, a water miscible alkylene glycol, a hydroxyalkyl cellulose gelling agent and water, buffered to have a pH within the range of 4.5-6.5 and having a viscosity

20

within the range of 10 Pa·s (10,000 cps) and preferably 50 to 200 Pa·s (50,000 to 200,000 cps).

Since they can be manufactured using processes, such as those according to the first aspect of the invention, which allow clumping to be avoided, an advantage of compositions in accordance with this aspect of the invention is that they can be produced consistently and within an acceptably narrow pH range.

In a third aspect, the invention provides a viscous hydrogel composition, for use in a topical treatment of a skin condition involving dry or inflamed skin, prepared or preparable by a method in accordance with the first aspect of the invention, and having a viscosity within the range of 10 Pa·s (10,000 cps) and preferably 50 to 200 Pa·s (50,000 to 200,000 cps)..

Unlike previous compositions, compositions in accordance with the second aspect of the invention are, and those prepared in accordance with the first aspect can be, buffered, for example by the inclusion therein of ionic buffers such as conventional weak acid/salt buffers. By so doing, it is easy to ensure that such compositions will have a pH within a physiologically acceptable pH range, and that any tendency they otherwise could have to clumping induced pH variation, or pH drift during storage and after application to the skin, is mitigated or reduced below an acceptable limit.

Accordingly, in embodiments of all the aspects of the invention, suitable buffering agents are selected so that the pH of and, in some embodiments, the osmotic pressure exerted by the composition is physiologically acceptable, not only immediately on application to the skin but, preferably, also for a sufficient period thereafter to prevent irritation through pH (or osmotic pressure) drift after application to the skin.

Suitable buffers include acetic acid/acetate, hydrochloric acid/citrate, citrophosphate, phosphate, phosphate buffered saline, and citric acid/citrate systems.

The preferred buffering agents are citric acid and a citrate, preferably sodium citrate, and, in preferred embodiments, the inventive composition has a pH within the range of 4.5-6.5, preferably within the range of 5-6 and, more preferably, of about 5.5. In preferred embodiments of the first aspect of the invention, buffering agents are included in the aqueous medium before the suspended polysaccharide thickening agent is mixed with said solution.

Preferably, the method in accordance with the first aspect of the invention is employed to prepare a composition in accordance with the second aspect of the invention.

The hydroxyalkyl cellulose gelling agent can be hydroxymethyl, hydroxyethyl or hydroxypropyl cellulose. The preferred such agent is hydroxyethyl cellulose.

It is preferred that the hydroxyalkyl cellulose gelling agent is insoluble or substantially insoluble in the water miscible alkylene glycol (when substantially pure). Suitable alkylene glycols include glycerol, dipropylene glycol, polyethylene glycol, propylene carbonate, propylene glycol, butylene glycol, pentylene glycol and hexylene glycol. The preferred alkylene glycol is propylene glycol.

It is preferred that the nitroimidazole drug is the sole pharmaceutically active agent used in methods and compositions in accordance with the invention. Metronidazole or tinidazole are the preferred nitroimidazole drugs, the most preferred being metronidazole.

Preferred embodiments of the invention have a viscosity within the range of 10 Pa·s (10,000 cps) and preferably 50 to 200 Pa·s (50,000 to 200,000 cps).

Preferably, compositions in accordance with or prepared by the invention are for use in treating skin conditions involving dry or inflamed skin, including rosacea, eczema and conditions involving infections responsive to anti-microbially active imidazole derivatives such as metronidazole. The latter include those conditions which are caused or exacerbated by organisms responsive to anti-microbially active imidazole derivatives, including infected fungating tumors and benign cutaneous ulcers.

It is preferred that compositions in accordance with or prepared by the invention exert a physiologically acceptable osmotic pressure.

- 5 In a further aspect, the invention provides the use of a composition in accordance with the second or third aspect of the invention or a composition prepared by a method in accordance with the first aspect of the invention, for the preparation of a medicament for use in treating a skin condition involving dry or inflamed skin, including rosacea, eczema and conditions involving infections responsive to anti-
10 microbially active nitroimidazole derivatives, preferably metronidazole (the latter including those conditions which are caused or exacerbated by organisms responsive to anti-microbially active imidazole derivatives). In another aspect, the invention comprises the use of a nitroimidazole drug for the preparation of a medicament in accordance with the second or third aspect of the invention, for use
15 in treating a skin condition involving dry or inflamed skin, preferably one of the aforementioned conditions.

- In a yet further aspect, the invention provides a method of treating a skin condition involving dry or inflamed skin, preferably rosacea, eczema or a condition
20 involving an infection responsive to an antimicrobially active nitroimidazole drug, preferably metronidazole, comprising topically applying a composition in

accordance with the second or third aspect of this invention to skin effected by said condition.

Preferred, non-limiting examples of the invention, in its various aspects, will now
5 be described.

Example 1

The materials employed in this example are set out in the following table.

	Metronidazole	0.75%	
10	Water	to 100%	
	Citric acid	Q.S. }	To provide pH 5.5
	Sodium Citrate	Q.S. }	
	Hydroxyethyl Cellulose	1.8%	
15	Propylene Glycol	5.0%	
	Methyl-p-benzoic acid ester	0.15%	
	Propyl-p-benzoic acid ester	0.05%	

In a first vessel, the metronidazole is dissolved in the water at a temperature of 35-
20 40°C and sufficient quantities of the buffering agents, citric acid and sodium citrate,
are then added to the resulting solution, to provide the finished composition with a
pH of 5.5. Conventional preservatives (not listed above) may also be included in
the solution.

In a separate vessel, the preservatives methyl-p-benzoic acid ester and propyl-p-benzoic acid ester are dissolved in the propylene glycol and the hydroxyethyl cellulose is added to the resulting solution, to form a suspension. This suspension is
5 then cooled to 10-15°C and then added to the first vessel, containing the buffered aqueous metronidazole solution, while the latter is vigorously stirred. Stirring is continued until the hydroxyethyl cellulose is fully hydrated. After the resulting mixture has become homogenous, it is allowed to stand for one day and the resulting gel is then packed.

10

Example 2

The same materials are employed in this example in the same quantities as are employed in Example 1 above. Sufficient quantities of citric acid and sodium citrate are dissolved in the required amount of water to provide the finished
15 composition with a pH of 5.5. Conventional preservations (not listed) can be included in this solution. In a separate vessel, the methyl-p-benzoic acid ester and the propyl-p-benzoic acid ester are dissolved in the propylene glycol, and the metronidazole followed by the hydroxyethyl cellulose are added to the resulting solution, to form a suspension. This suspension is then cooled to 10-15°C and
20 added to a second vessel containing the citrate buffered aqueous solution, while the latter is vigorously stirred. Stirring is continued until the hydroxyethyl cellulose is

fully hydrated. After the resulting mixture has become homogenous, it is allowed to stand for one day and the resulting gel is then packed.

Example 3-12

- 5 Further compositions are made up using the materials and methods described in Examples 1 and 2, but with the citric acid and sodium citrate being replaced with acetic acid and sodium acetate (examples 3 and 4), hydrochloric acid and sodium citrate (examples 5 and 6), disodium hydrogen orthophosphate and citric acid (examples 7 and 8), disodium hydrogen orthophosphate and potassium dihydrogen
10 orthophosphate (examples 9 and 10), and disodium hydrogen orthophosphate, potassium dihydrogen orthophosphate and sodium chloride (examples 11 and 12), respectively.

Example 13

- 15 Twelve patients suffering from rosacea with mild to severe erythema and a minimum of three pustules or papules on the face were treated with a 0.75% metronidazole gel over a period of nine weeks. The metronidazole gel was topically applied on a twice daily basis. By week nine, the papule/pustule count was reduced by 50% or more in all patients, with 100% clearing in 75% of the
20 patients. The degree of erythema exhibited by all of the patients in the group improved significantly, from being relatively severe at the outset to being relatively mild at the end of the nine week period of the test.

1

CLAIMS

1. A method of preparing a viscous hydrogel composition, for use in a topical treatment of a skin condition involving dry or inflamed skin, including a
- 5 pharmaceutically active agent, a polysaccharide, a water-miscible organic solvent and water, comprising the steps of suspending the polysaccharide in the water-miscible organic solvent and mixing the resulting polysaccharide suspension into the aqueous medium, thereby to hydrate the polysaccharide and to form a viscous hydrogel composition, wherein the pharmaceutically active agent is an antimicrobially active
- 10 nitroimidazole drug, the water-miscible organic solvent is a water-miscible alkylene glycol, and the composition is buffered to have a pH within the range of 4.5-6.5.
2. A method as claimed in claim 1, wherein the nitroimidazole drug is dissolved in the aqueous medium, or suspended or dissolved in the water miscible
- 15 organic solvent, before said suspension is mixed with said aqueous medium.
3. A method as claimed in claim 2, wherein the nitroimidazole drug is suspended or dissolved in the water-miscible organic solvent, before the polysaccharide is suspended therein.
- 20
4. A method as claimed in claim 2, wherein the nitroimidazole drug is dissolved in the aqueous medium at a temperature of 15-50°C, 25-40°C, or 35-40°C.

5. A method as claimed in any of claims 1-4, wherein the polysaccharide suspension is at a temperature of 4-30°C, preferably 15-25°C, or 4-15°C, preferably 10-15°C, immediately prior to mixing with the aqueous medium.

5 6. A method as claimed in any of claims 1-5, wherein the nitroimidazole drug is metronidazole or tinidazole and, preferably metronidazole.

7. A method as claimed in any of claims 1-6, wherein the buffer is included in the aqueous medium, preferably before the suspended polysaccharide is mixed with
10 said medium.

8. A method as claimed in any of claims 1-7, wherein the buffer comprises an acetic acid/acetate, hydrochloric acid/citrate, citric acid/citrate, citro-phosphate, phosphate, or phosphate buffered saline, buffer system.
15

9. A method as claimed in claim 8, wherein the buffer system comprises citric acid and a citrate, preferably sodium citrate.

10. A method as claimed in any of claims 1-9, wherein the composition has a
20 pH preferably within the range of 5-6 and, more preferably, of about 5.5.

AMENDED SHEET
IPEA/EP

11. A method as claimed in any of claims 1-10, wherein the polysaccharide is non-ionic cellulose ester, ether, hydroxy-ether, or hydroxy-ester, or a non-ionic starch derivative.

5 12. A method as claimed in any of claims 1-11, wherein the polysaccharide is hydroxyalkyl cellulose.

13. A method as claimed in claim 11 wherein the polysaccharide is a methyl, ethyl or propyl cellulose ester, ether, hydroxy-ether, or hydroxy-ester.

10

14. A method as claimed in claim 12, wherein the hydroxyalkyl cellulose is hydroxymethyl, hydroxyethyl or hydroxypropyl cellulose, preferably, hydroxyethyl cellulose.

15 15. A method as claimed in any of claims 1-14, wherein the polysaccharide is insoluble or substantially insoluble in the water miscible organic solvent.

16. A method as claimed in any of claims 1-15, wherein the water-miscible alkylene glycol is glycerol, dipropylene glycol, propylene glycol, butylene glycol,
20 pentylene glycol or hexylene glycol, and, preferably, propylene glycol.

17. A viscous hydrogel composition, for use in a topical treatment of a skin condition involving dry or inflamed skin, prepared by a method as claimed in any

AMENDED SHEET
IPEA/EP

of claims 1-16, and having a viscosity within the range of 10 Pa·s (10,000 cps) and preferably 50 to 200 Pa·s (50,000 to 200,000 cps).

18. A viscous hydrogel composition, for use in a topical treatment of a skin
5 condition involving dry or inflamed skin, comprising an antimicrobially active
nitroimidazole drug, a water miscible alkylene glycol, a hydroxyalkyl cellulose
gelling agent and water, buffered to have a pH within the range of 4.5-6.5, and
having a viscosity within the range of 10 Pa·s (10,000 cps) and preferably 50 to 200
Pa·s (50,000 to 200,000 cps).

10 19. A composition as claimed in claim 18, devoid of any additional
pharmaceutically active agent or agents.

20. A composition as claimed in claim 19, wherein the antimicrobially active
15 nitroimidazole drug is the sole pharmaceutically active agent.

21. A composition as claimed in any of claims 17-20, wherein the hydroxyalkyl
cellulose gelling agent is hydroxymethyl, hydroxyethyl or hydroxypropyl cellulose
and, preferably, hydroxyethyl cellulose.

20 22. A composition as claimed in any of claims 17-21, wherein the
antimicrobially active nitroimidazole drug is metronidazole or tinidazole, and
preferably metronidazole.

AMENDED SHEET
IPEA/EP

23. A composition as claimed in any of claims 17-22 further comprising an acetic acid/acetate, hydrochloric acid/citrate, citric acid/citrate, citro-phosphate, phosphate, or phosphate buffered saline, buffer system.

5

24. A composition as claimed in claim 23 comprising citric acid and a citrate, preferably sodium citrate, as buffering agents.

10

25. A composition as claimed in any of claims 17-24 having a pH preferably within the range of 5-6 and, more preferably, of about 5.5.

15

26. A composition as claimed in any of claims 17-25, wherein the skin condition is rosacea, eczema or involves an infection responsive to the antimicrobially active nitroimidazole drug, preferably metronidazole.

20

27. A composition as claimed in any of claims 17-26, wherein the hydroxyalkyl cellulose gelling agent is insoluble or substantially insoluble in the water miscible alkylene glycol.

28. A composition as claimed in any of claims 17-27, wherein the water miscible alkylene glycol is glycerol, dipropylene glycol, propylene glycol, butylene glycol, pentylene glycol or hexylene glycol, and, preferably, propylene glycol.

AMENDED SHEET
IPEA/EP

29. A method as claimed in any of claims 1-16, wherein the composition is in accordance with any one of claims 18-20.


30. Use of a composition as claimed in any of claims 17-28 for the preparation
5 of a medicament for use in treating a skin condition involving dry or inflamed skin, preferably rosacea, eczema or a condition involving an infection responsive to an antimicrobially active nitroimidazole drug, preferably metronidazole.

31. Use of a nitroimidazole drug for the preparation of a medicament as claimed
10 in any of claims 17-28 for use in treating a skin condition involving dry or inflamed skin, preferably rosacea, eczema or a condition involving an infection responsive to an antimicrobially active nitroimidazole drug, preferably metronidazole.

32. A method of treating a skin condition involving dry or inflamed skin,
15 preferably rosacea, eczema or a condition involving an infection responsive to an antimicrobially active nitroimidazole drug, preferably metronidazole, comprising topically applying a composition as claimed in any of claims 17-29 to skin effected by said condition.

AMENDED SHEET
IPEA/EP

DECLARATION AND POWER OF ATTORNEY FOR ORIGINAL U.S. PATENT APPLICATION



Attorney's Docket No. _____

As a below-named inventor, I hereby declare that

My residence, post office address and citizenship are stated below next to my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:
MAGNETIZABLE DEVICE the specification of which,

(check one)

1. ☐ is attached hereto.
2. ☐ was filed on _____ as
U.S. Application No. _____
and was amended on _____
3. ☒ was filed on 17th November 1997 as
International PCT Application No. PCT/GB97/03152
and was amended on _____

RECEIVED
FEB 16 2000
TECHNICAL SERVICES 3700

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, CFR § 1.56.

Prior Foreign Application(s)

I hereby claim foreign priority benefits under Title 35, United States code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

<u>9623851.4</u>	<u>Great Britain</u>	<u>16th November 1996</u>	Priority Benefits Claimed?
(Application No.)	(Country)	(Filing Date)	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>
_____	_____	_____	Yes <input type="checkbox"/> No <input type="checkbox"/>
(Application No.)	(Country)	(Filing Date)	

Provisional Application(s)

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

_____	_____
(Application No.)	(Filing Date)
_____	_____
(Application No.)	(Filing Date)

RECEIVED
FEB 14 2000
TECHNICAL SERVICES 3700

Prior U.S. Application(s)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

_____ (Application No.)	_____ (Filing Date)	_____ (Status - patented, pending, abandoned)
----------------------------	------------------------	--

_____ (Application No.)	_____ (Filing Date)	_____ (Status - patented, pending, abandoned)
----------------------------	------------------------	--

Power of Attorney

And I hereby appoint the law firm of **Beyer & Weaver, LLP** and all practitioners who are associated with the Customer Number 022434 as my principal attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Direct Correspondence To:

Customer Number: 022434

BEYER & WEAVER, LLP
P.O. Box 61059
Palo Alto, CA 94306



Direct Telephone Calls To:

Steve D Beyer at telephone number (650) 493-2100

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Typewritten Full Name of
Sole or First Inventor:

Eric Leigh MAYES

Citizenship: US

Inventor's signature:

[Signature]

Date of Signature: May 13th 1999

Residence: (City)

Bath

(State/Country) Great Britain

Post Office Address:

5 Brock Street, Bath BA1 26N, Great Britain

Full Name of Second Joint
Inventor (if any):

Malvin Nicolas TYLER

Citizenship: British

Inventor's signature:

[Signature]

Date of Signature: MAY 11th 1999

Residence: (City)

Bath

(State/Country) Great Britain

Post Office Address:

9 The Circus, Bath BA1 2EW, Great Britain

[Signature]